Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.63 |
| ▸ | THPO | P40225 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.48 |
| ▸ | MME | P08473 | 6/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3014643 | 1.00 | ACE (0.74) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL1059519 | 1.00 | ACE (0.74) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL931221 | 0.85 | ACE (1.00) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL6927677 | 0.85 | ACE (0.71) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL930664 | 0.85 | ACE (0.71) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL23835494 | 0.85 | ACE (0.71) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL525145 | 0.85 | ACE (1.00) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL931219 | 0.85 | ACE (1.00) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL928750 | 0.85 | ACE (1.00) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL929422 | 0.85 | ACE (1.00) | ACEKDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 492 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636312-B2 | Gold clusters (AuCs), composition and method for treatment of liver cirrhosis | WUHAN VAST CONDUCT SCIENCE FOUNDATION CO., LTD. (CN) | 2026-05-26 | — | — | US | claimed |
| US-12533378-B2 | Treatment of adverse effects caused by atypical antipsychotics | SHENZHEN PROFOUND VIEW PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2026-01-27 | — | — | US | claimed |
| US-12498357-B2 | Amino acid analysis method | SHIMADZU CORPORATION (JP) | 2025-12-16 | — | — | US | claimed |
| US-12486178-B2 | Copper nanoclusters, composition comprising the same, and treatment of multiple sclerosis | Shenzhen Profound-View Pharma Tech Co., Ltd (CN) | 2025-12-02 | — | — | US | claimed |
| US-20250249036-A1 | Composition and Method for treatment of diabetes | SHENZHEN PROFOUND VIEW PHARMACEUTICAL TECH CO LTD (CN) | 2025-08-07 | — | — | US | claimed |
| US-12371339-B2 | Copper nanoclusters, thymine-modified hyaluronic acid and poly(copper nanoclusters), method for preparing the same, and application thereof | Shenzhen Profound-View Pharma Tech Co., Ltd (CN) | 2025-07-29 | — | — | US | claimed |
| US-12310985-B2 | Composition and method for treatment of diabetes | SHENZHEN PROFOUND VIEW PHARMACEUTICAL TECHNOLOGY (CN) | 2025-05-27 | — | — | US | claimed |
| US-20250064970-A1 | L-N-isobutyryl cysteine (L-NIBC)-bound gold cluster Au18(L-NIBC)14, compositions and applications thereof | SHENZHEN PROFOUND VIEW PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2025-02-27 | — | — | US | claimed |
| US-20240391792-A1 | COPPER NANOCLUSTERS, COMPOSITION COMPRISING THE SAME, AND TREATMENT OF MULTIPLE SCLEROSIS | Shenzhen Profound-View Pharma Tech Co., Ltd (CN) | 2024-11-28 | — | — | US | claimed |
| EP-4466274-A1 | L-N-ISOBUTYRYL CYSTEINE (L-NIBC) -BOUND GOLD CLUSTER AU 18(L-NIBC) 14 COMPOSITIONS AND APPLICATIONS THEREOF | Shenzhen Profound View Pharmaceutical Technology Co., Ltd. (CN) | 2024-11-27 | — | — | EP | claimed |
| WO-2005040751-A2 | DECONTAMINATION AND CONCENTRATION KIT FOR MYCOBACTERIA | SALUBRIS INC. (US) | 2005-05-06 | — | — | WO | claimed |
| US-20050089948-A1 | Decontamination and concentration kit for mycobacteria | SALUBRIS, INC. | 2005-04-28 | — | — | US | claimed |
| WO-2004012652-A9 | TREATMENT OF MULTIPLE SCLEROSIS WITH BRAIN TARGETED ANTI OXIDANT COMPOUNDS | YISSUM RES DEV CO (IL) | 2004-06-17 | — | — | WO | claimed |
| WO-2004012652-A2 | TREATMENT OF MULTIPLE SCLEROSIS WITH BRAIN TARGETED ANTI OXIDANT COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-02-12 | — | — | WO | claimed |
| EP-1242070-A4 | TREATMENT OF ISCHEMIC BRAIN INJURIES WITH BRAIN TARGETTED ANTIOXIDANT COMPOUNDS | YISSUM RES DEV CO (IL) | 2003-05-28 | — | — | EP | claimed |
| US-20030083266-A1 | Treatment of ischemic brain injuries with brain targeted antioxidant compounds | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2003-05-01 | — | — | US | claimed |
| EP-1242070-A2 | TREATMENT OF ISCHEMIC BRAIN INJURIES WITH BRAIN TARGETTED ANTIOXIDANT COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-09-25 | — | — | EP | claimed |
| US-6369106-B1 | SULFHYDRYL CONTAINING COMPOUND AS ANTIOXIDANT | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-04-09 | — | — | US | claimed |
| WO-2001047469-A2 | TREATMENT OF ISCHEMIC BRAIN INJURIES WITH BRAIN TARGETTED ANTIOXIDANT COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-07-05 | — | — | WO | claimed |
| WO-1990013538-A1 | ORGANIC SALTS OF CYSTEINE DERIVATIVES | AKTIEBOLAGET DRACO (SE) | 1990-11-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371339-B2 | Copper nanoclusters, thymine-modified hyaluronic acid and poly(copper nanoclusters), method for preparing the same, and application thereof | CD44, UMPS, CSGALNACT1 | ACE 2271/4885KDM4E 4754/4885MAPT 1808/4885 |
| US-12533378-B2 | Treatment of adverse effects caused by atypical antipsychotics | FABP7, FABP4, LIPC | ACE 1483/4885KDM4E 4588/4885MAPT 801/4885 |
| US-20030083266-A1 | Treatment of ischemic brain injuries with brain targeted antioxidant compounds | GPX4, GPX1, TXN2 | ACE 3297/4885KDM4E 4595/4885MAPT 1162/4885 |
| US-12636312-B2 | Gold clusters (AuCs), composition and method for treatment of liver cirrhosis | FABP1, ALB, CSTB | ACE 1412/4885KDM4E 4638/4885MAPT 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.